The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators

Surgery

Volumn 134, Issue 5, 2003, Pages 827-834

  Georgiannos, Stavros N ^a   Renaut, Andrew ^a   Goode, Anthony W ^a   Sheaff, Michael ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ESTROGEN RECEPTOR; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

EID: 0348134670     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(03)00292-7     Document Type: Article

References (38)

1. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response [Review]. Sem Hemat 1985;22: 27-40.
2. Jarry A, Cerf-Bensussan N, Brousse N, Guy-Grand D, Muzeau F, Potet F. Same peculiar subset of HML1+ lymphocytes present within normal intestinal epithelium is associated with tumoral epithelium of gastrointestinal carcinomas. Gut 1988;29:1632-8.
3. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immun 1993;150:3459-70.
4. Smith KA. T-cell growth factor [Review]. Immun Rev 1980; 51:337-57.
5. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986;232:727-32.
6. Waldmann TA. The interleukin-2 receptor [Review]. J Biol Chem 1991;266:2681-4.
7. Swain SL. Lymphokines and the immune response: the central role of interleukin-2 [Review]. Curr Op Immun 1991;3:304-10.
8. Bhan AK, DesMarais CL. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Canc Inst 1983;71:507-16.
9. Rowe DJ, Beverley PC. Characterization of breast cancer infiltrates using monoclonal antibodies to human leukocyte antigens. B J Cancer 1984;49:149-59.
10. Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary carcinomas: immunohistochemical analysis with monoclonal antibodies. Int J Cancer 1985;35: 753-62.
11. Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Canc Immun Immunoth 1986;23:169-78.
12. Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Path 1987;152:275-85.
13. Bilik R, Mor C, Hazaz B, Moroz C. Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Canc Immun Immunoth 1989;28:143-7.
14. Naukkarinen A, Syrjanen KJ. Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas - correlation with tumor differentiation. J Path 1990;160:217-22.
15. Whitford P, George WD, Campbell AM. Flow cytometric analysis of tumor infiltrating lymphocyte activation and tumor cell MHC class I and II expression in breast cancer patients. Canc Lett 1992;61:157-64.
16. Black MM. Immunopathology of breast cancer. Pathobiol Annu 1977;7:213-30.
17. Hadden JW. The immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol 1999;21: 79-101.
18. Tonini G, Nunziata C, Prete SP, Pepponi R, Turriziani M, Masci G, et al. Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. Cancer Immunol Immunother 1998;47: 157-66.
19. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999;6: 350-63.
20. Maeda T, Matsubara H, Sugaya M, Miyazawa Y, Gunji Y, Ochiai T, et al. Loss of tumorigenicity of human breast cancer cells engineered to produce IL-2, IL-4 or GM-CSF in nude mice. Int J Oncol 1999;15:943-7.
21. Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, et al. High dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Bone Marrow Transplant 2000;25:19-24.
22. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000;23: 154-60.
23. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23:570-80.
24. Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, et al. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 2001;166:1156-68.
25. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol 2001;19:634-44.
26. Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen ER. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg 2001;94:287-92.
27. Euhus DM, Kimura L, Arnold B. Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures. Ann Surg Oncol 1997;4:432-9.
28. Ferron A, Perez-Ayala M, Concha A, Cabrera T, Redondo M, Oliva MR, et al. MHC class I and II antigens on gastric carcinomas and autologous mucosa. J Immunogenet 1989;16:413-23.
29. Redondo M, Concha A, Oldiviela R, Cueto A, Gonzalez A, Garrido F, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991;51:4948-54.
30. Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 1995;22: 299-310.
31. Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, et al. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-70.
32. Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 1998;5:1400-9.
33. Putzer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ, Graham FL. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998;9:707-18.
34. Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 1998;160:2531-8.
35. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996;3:11-7.
36. Jurgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, et al. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 1997;5:54-61.
37. Everse LA, Renes IB, Jurgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HF, et al. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int J Cancer 1997;72: 1003-7.
38. Den Otter W, Balemans L, Battermann JJ, Bernsen MR, Cadee JA, Dobrowolski Z, et al. Local low-dose IL-2 therapy. Hepatogastroenterology 1999;46(Suppl 1):1280-6.